RT Journal Article SR Electronic T1 Detection of Left Ventricular Systolic Dysfunction from Electrocardiographic Images JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.06.04.22276000 DO 10.1101/2022.06.04.22276000 A1 Veer Sangha A1 Arash A Nargesi A1 Lovedeep S Dhingra A1 Bobak J Mortazavi A1 Antônio H Ribeiro A1 Cynthia A Brandt A1 Edward J Miller A1 Antonio Luiz P Ribeiro A1 Eric J Velazquez A1 Harlan M Krumholz A1 Rohan Khera YR 2022 UL http://medrxiv.org/content/early/2022/06/06/2022.06.04.22276000.abstract AB Left ventricular (LV) systolic dysfunction is associated with over 8-fold increased risk of heart failure and 2-fold risk of premature death. To allow early detection by clinicians, we developed a layout-independent deep learning model that identifies LV systolic dysfunction directly from images of electrocardiograms (ECGs). Overall, 393,910 ECGs with paired echocardiograms were used for model development. The model performed well across multiple image formats (AUROC 0.91, AUPRC 0.69), and two external sets of real-world ECG images from an outpatient academic center (AUROC 0.93, AUPRC 0.69) and a rural hospital system (AUROC 0.91, AUPRC 0.89). Class-discriminative patterns localized to the anterior and anteroseptal leads corresponding to the left ventricle, regardless of ECG layout. A positive ECG screen in individuals with preserved LV ejection fraction was associated with 4-fold increased risk of developing LV systolic dysfunction in future. This approach represents an automated and accessible screening strategy for LV systolic dysfunction.Competing Interest StatementDr. Mortazavi reported receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work; in addition, Dr. Mortazavi has a pending patent on predictive models using electronic health records (US20180315507A1). Antonio H. Ribeiro is funded by Kjell och Marta Beijer Foundation. Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company. Dr Ribeiro is supported in part by CNPq (310679/2016-8 and 465518/2014-1) and by FAPEMIG (PPM-00428-17 and RED-00081-16). Mr. Sangha and Dr. Khera are the coinventors of U.S. Provisional Patent Application No. 63/346,610, Articles and methods for format independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning. Dr. Khera is also a founder of Evidence2Health, a precision health platform to improve evidence-based care.Funding StatementThis study was supported by research funding awarded to Dr. Khera by the Yale School of Medicine and grant support from the National Heart, Lung, and Blood Institute of the National Institutes of Health under the award K23HL153775. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Yale Institutional Review Board, which approved the study protocol and waived the need for informed consent as the study represents secondary analysis of existing data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript